AMGEN T-VEC_Atezolizumab The goal of this study is to evaluate the safety of intrahepatic injection (directly into the liver) of talimogene laherparepvec in combination with intravenously administered atezolizumab in subjects with triple negative breast cancer and colorectal cancer with liver metastases. (Aktiv)
Antonio Phase II Studie zu IMM-101 als adjuvante Therapie bei fortgeschrittenem Darmkrebs mit Mikrosatelliteninstabilität (Aktiv)
Erstlinie
AIO-KRK-0519 (FIRE-8) Prospective, Randomized, Open, Multicenter Phase II Trial to Investigate the Efficacy of Trifluridine/Tipiracil Plus Panitumumab Versus Trifluridine/Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer (Aktiv)
GOBLET A phase 1 / 2 multiple-indication biomarker, safety, and efficacy study in advanced or metastatic Gastrointestinal cancers explOring treatment comBinations with peLarEorep and aTezolizumab (Aktiv)
Zweitlinie oder später
AIO-KRK-0418 (FIRE-9) Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer Prospective, Randomized, Open, Multicenter Phase III Trial to Investigate the Efficacy of Active Post-resection/Ablation Therapy in Patients With Metastatic Colorectal Cancer (Aktiv)
LICC L-BLP25 Studie L-BLP25 in Patients with Colorectal Carcinoma after curative resection (Aktiv)
NuTide:323 Eine randomisierte, offene Phase-II-Studie zur Optimierung der Dosis/des Behandlungsplans mit NUC-3373/Leucovorin/Irinotecan plus Bevacizumab (NUFIRI-bev) im Vergleich zu 5-FU/Leucovorin/Irinotecan plus Bevacizumab (FOLFIRI-bev) zur Behandlung von Patienten Mit zuvor behandeltem nicht resezierbarem metastasiertem Darmkrebs Phase II Studie zu NUC-3373/leucovorin/irinotecan plus Bevacizumab vs 5-FU/leucovorin/irinotecan plus Bevacizumab bei Darmkrebs Eine Studie von NUC-3373 in Kombination mit anderen Wirks (Aktiv)